Literature DB >> 32046285

NAFLD Preclinical Models: More than a Handful, Less of a Concern?

Yvonne Oligschlaeger1, Ronit Shiri-Sverdlov1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver diseases ranging from simple steatosis to non-alcoholic steatohepatitis, fibrosis, cirrhosis, and/or hepatocellular carcinoma. Due to its increasing prevalence, NAFLD is currently a major public health concern. Although a wide variety of preclinical models have contributed to better understanding the pathophysiology of NAFLD, it is not always obvious which model is best suitable for addressing a specific research question. This review provides insights into currently existing models, mainly focusing on murine models, which is of great importance to aid in the identification of novel therapeutic options for human NAFLD.

Entities:  

Keywords:  NAFLD; mouse models; multifactorial disease; translational value

Year:  2020        PMID: 32046285     DOI: 10.3390/biomedicines8020028

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  7 in total

Review 1.  Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease.

Authors:  Ronan Thibaut; Matthew C Gage; Inès Pineda-Torra; Gwladys Chabrier; Nicolas Venteclef; Fawaz Alzaid
Journal:  FEBS J       Date:  2021-05-02       Impact factor: 5.622

2.  A human pluripotent stem cell model for the analysis of metabolic dysfunction in hepatic steatosis.

Authors:  Matthew C Sinton; Jose Meseguer-Ripolles; Baltasar Lucendo-Villarin; Sara Wernig-Zorc; John P Thomson; Roderick N Carter; Marcus J Lyall; Paul D Walker; Alpesh Thakker; Richard R Meehan; Gareth G Lavery; Nicholas M Morton; Christian Ludwig; Daniel A Tennant; David C Hay; Amanda J Drake
Journal:  iScience       Date:  2020-12-11

Review 3.  Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments.

Authors:  Cheng Peng; Alastair G Stewart; Owen L Woodman; Rebecca H Ritchie; Cheng Xue Qin
Journal:  Front Pharmacol       Date:  2020-12-03       Impact factor: 5.810

4.  Effect of voluntary exercise upon the metabolic syndrome and gut microbiome composition in mice.

Authors:  Timothy M Moore; Anthony Terrazas; Alexander R Strumwasser; Amanda J Lin; Xiaopeng Zhu; Akshay T S Anand; Christina Q Nguyen; Linsey Stiles; Frode Norheim; Jennifer M Lang; Simon T Hui; Lorraine P Turcotte; Zhenqi Zhou
Journal:  Physiol Rep       Date:  2021-11

5.  Meta-Inflammation and De Novo Lipogenesis Markers Are Involved in Metabolic Associated Fatty Liver Disease Progression in BTBR ob/ob Mice.

Authors:  Lucas Opazo-Ríos; Manuel Soto-Catalán; Iolanda Lázaro; Aleix Sala-Vila; Luna Jiménez-Castilla; Macarena Orejudo; Juan Antonio Moreno; Jesús Egido; Sebastián Mas-Fontao
Journal:  Int J Mol Sci       Date:  2022-04-02       Impact factor: 5.923

6.  NASH and Systemic Complications: From Basic to Clinical Research.

Authors:  Sabine Baumgartner; Ronit Shiri-Sverdlov
Journal:  Biomedicines       Date:  2021-12-14

Review 7.  Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH.

Authors:  Ryan D Welch; Cyrielle Billon; McKenna Losby; Gonzalo Bedia-Diaz; Yuanying Fang; Amer Avdagic; Bahaa Elgendy; Thomas P Burris; Kristine Griffett
Journal:  Metabolites       Date:  2022-03-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.